In COVID-19 patients, SGLT2-inhibitor canagliflozin showed a reduction in interleukin-6 (IL-6) levels, which are crucial in triggering cytokine release syndrome (CRS) [183]. The gene discussed is IL6; the disease is congenital rubella syndrome.